Synthetech saw its earnings rise from $113,000 to $657,000 in its fourth quarter. However the company said the biopharmaceuticals market is showing some weakness, the difficult financing environment could impair drug development projects and that some major pharmaceutical companies are reducing their outsourcing expenses.
Portland Business Journal
Monday, 8 June 2009
Synthetech reports boost in earnings, gloomy outlook
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment